The biosynthetic pathway of hibarimicin (HBM) was proposed on the basis of the experimental results obtained by using blocked mutants of Microbispora rosea subsp. hibaria TP-A0121, the HBM producer. In its biosynthesis, the oxidative coupling of the aromatic undecaketide unit generates a symmetrical aglycon HMP-Y1 (hibarimicin-mutant product Y1), which is oxidatively modified to hibarimicinone, the HBM aglycon. The following glycosylation of hibarimicinone gives rise to the HBM complex. We identified that HMP-Y1 prepared by methanolysis of HMP-Y6, a glycosylated metabolite from a blocked mutant, was the key intermediate: transformation of 13C-labeled HMP-Y1 to HBM B was confirmed by NMR measurements. Mutant strain produced another type of aglycon HMP-P1 in which the coupled polyketide units were intramolecularly bridged by the ether bond. This metabolite also arose by the spontaneous elimination of methanol molecule from hibarimicinone.
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Hibarimicins
(HBMs) were discovered from Microbispora rosea subsp. hibaria TP-A0121 as a complex of analogs in the screening for tyrosine kinase inhibitors1,2).
The strain TP-A0121 produces more than ten HBM components detectable on TLC. Structural study of the major components revealed that HBM is the glycosylated aromatic polyketide derived from two undecaketides differing from each other by the number and type of deoxysugars attached on the amicetoses. HBM is one of the most complicated and largest molecules among the aromatic polyketide dimers of microbial metabolites. In the preceeding paper, we demonstrated that the aglycon of HBM arises by dimerization of two monomeric units of undecaketide through decarboxylation and skeltal rearrangement3). This study was attempted to elucidate the 
Methanolysis
Glycosylated metabolites were subjected to acid- Four deoxysugars of 6 were the same ones found in HBM. 5 was also the major product of another mutant AN-0623.
The most attractive metabolite HMP-Y6 (3) was obtained from the culture broth of strain AN-0416. This symmetric compound was the dimer of the west half of HBM B (1). Since the transformation from 3 to 1 presumably requires two oxidation steps, we speculated that 3 or HMP-Y1 (4) Table 2 . Bioconversion of HMP-Y1 and hibarimicinone by growing culture of blocked mutant AN-0554. 
